Étiquette : Endocrinology

ERBC GROUP

by jbertholdin Institutions, Service Providers & others

ERBC GROUP

About the company

ERBC group is a leader in discovery and non-clinical studies, offering to healthcare and chemical professionals a comprehensive range of discovery and preclinical models, regulatory pre-IND package and consultancy services to de-risk innovation and improve R&D productivity.

About the solution

At ERBC Group, THEY STRATEGIZE your approach to make your drug development a SUCCESS:
– Build on most relevant translational models
– Select best predictive biomarkers
– Choose state-of-the-art technologies.

Website
Key information

–  Therapeutic areas: Oncology – Cancer, Immunology, Inflammation, Neurology – Neurosciences, Cell and gene therapies, Cardiovascular, Infectious diseases, Metabolic diseases – Hepatology – Diabetes, Gastroenterology, Respiratory, Ophthalmology, Allergy, Dermatology, Orthopedics, Central nervous system, Nephrology, Cardiology, Pulmonology, Endocrinology, Hematology

–  Based in: Baugy, Toulouse, Lyon, Orleans (FRANCE)

–  Employees: 201-500

–  Created in: 2019

CROSSJECT

by jbertholdin Biotech, Pharma

CROSSJECT

About the company

Crossject SA is an emerging specialty pharma company based in France and the U.S. It is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it was awarded a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company’s award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing.
The Company’s other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks.

About the solution

ZENEO is a pre-set in factory needle free device, it enables the easy and safe injection of a drug in only two steps, press and push into the injection site, even through clothing if necessary.

ZENEO has demonstrated through several Human Factors studies that it can be used easily and quickly even by naïve users even during an emergency situation.

There is no needle, which is a real advantage in terms of risk of laceration during injection and/or potential cross-contamination for the rescuer, or further down the disposal chain.

Website
Key information

–  Therapeutic areas: Epilepsy, Allergy, Endocrinology, Asthma

–  Based in: Dijon (FRANCE) Affiliate in Boston (USA)

–  Employees: 51 – 200

– Created in: 2001

H.A.C PHARMA

by jbertholdin Biotech, Pharma

H.A.C PHARMA

About the company

H.A.C. Pharma is a European pharmaceutical company incorporated in 2007 in France. H.A.C. Pharma markets and promotes high therapeutic value drugs, especially in pathologies with reduced alternatives for the patient.

The company works with a network of trusted distributors in 6 European countries (Spain, Italy, Belgium, Austria, Switzerland and Portugal) and directly in France with its own sales force.

The company’s drugs are mainly promoted to specialists in hospital setup in the area of endocrinology, neuropsychiatry, gynecology, onco-hematology and gastroenterology.

About the solution

H.A.C. Pharma is your partner of choice to launch your medicines in Europe: from clinical assessment of medical needs through go-to-market strategy, early-access program and full registration, importation and distribution, to promotion to specialists.

Website
Key information

–  Therapeutic areas: Neurology and CNS, Endocrinology, Hemato-oncology, Autoimmune diseases, Cardiology, Gynecology

–  Based in: Caen (FRANCE)

–  Employees: 11 – 50

– Created in: 2007

CONTACT
Philippe BissayCEO

philippe.bissay@hacpharma.com